Cipla Limited
CIPLA · Pharma · NSE
₹1,389
Current Market Price
Fair Value (DCF)
₹1,218
Discount to FV
-12.3%
Updated 10h ago
YieldIQ Score
45/100
Piotroski F-Score
5/9
Economic Moat
Narrow
Confidence
71%
ROE
11.3%
Debt/Equity
0.02
WACC
9.5%
Market Cap
₹1.12 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.1%
Return on capital employed
EV / EBITDA
15.5×
Enterprise multiple
Debt / EBITDA
0.1×
Leverage vs earnings
Interest Coverage
96.9×
EBIT covers interest
Current Ratio
3.44×
Short-term liquidity
Asset Turnover
0.66×
Revenue per ₹ of assets
Revenue CAGR (3Y)
1.8%
3-year revenue growth
Revenue CAGR (5Y)
4.4%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,389.4
Bear case
Margin of Safety -856.9%
Implied upside -89.5%
Base case
Margin of Safety -16.3%
Implied upside -14.0%
Bull case
Margin of Safety +13.0%
Implied upside +14.9%
Ratio Trends
CIPLA · last 9 annual periods
ROE
11.3%
ROCE
18.1%
Operating Margin
—
Debt / Equity
0.02×
PE
25.5×
EV / EBITDA
15.5×
Historical Financials
CIPLA · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹21.6K Cr | ₹22.5K Cr | ₹25.4K Cr | ₹27.1K Cr | ₹27.7K Cr | +6.4% |
| EBITDA | ₹4588 Cr | ₹5152 Cr | ₹6824 Cr | ₹7860 Cr | ₹6355 Cr | +8.5% |
| EBIT | ₹3600 Cr | ₹4148 Cr | ₹5792 Cr | — | — | +12.6% |
| PAT | ₹2517 Cr | ₹2802 Cr | ₹4122 Cr | ₹5273 Cr | ₹3879 Cr | +11.4% |
| EPS (diluted) | ₹31.17 | ₹34.69 | ₹51.01 | — | — | +13.1% |
| CFO | ₹3326 Cr | ₹3238 Cr | ₹4134 Cr | ₹5005 Cr | ₹3940 Cr | +4.3% |
| CapEx | ₹-701 Cr | ₹-1183 Cr | ₹-1349 Cr | ₹-1548 Cr | ₹-3079 Cr | — |
| FCF | ₹2625 Cr | ₹2055 Cr | ₹2785 Cr | ₹3457 Cr | ₹861 Cr | -24.3% |
| Total Assets | ₹27.1K Cr | ₹29.5K Cr | ₹32.7K Cr | ₹37.4K Cr | ₹42.5K Cr | +11.9% |
| Total Debt | ₹1056 Cr | ₹803 Cr | ₹559 Cr | ₹438 Cr | ₹614 Cr | -12.7% |
| Shareholders' Equity | ₹20.8K Cr | ₹23.4K Cr | ₹26.7K Cr | ₹31.2K Cr | ₹34.4K Cr | +13.4% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
CIPLA vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
 DRREDDY DRREDDY | — | — | Pending | 11.4% | 24.4× |
 LUPIN Lupin Limited | +16.7%+20.1% upside | 52 | Near Fair Value | 23.8% | 19.8× |
 MANKIND Mankind Pharma Limited | -122.7%-55.1% upside | 40 | Above Fair Value | 11.7% | — |
 AUROPHARMA AUROPHARMA | — | — | Pending | 9.2% | 21.4× |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹47.50/sh
Last payout
2025-06-27
₹16.00
Peak payout
₹16.00
Trailing yield
1.15%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Cipla Limited (CIPLA.NS) trades at 1389.40 vs a model fair value of 1218.32, a gap of -12.3%. Piotroski F-score: 5/9. Moat label: Narrow....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of CIPLA →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for CIPLA →
Compare
Head-to-head with peers
Compare CIPLA side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse CIPLANow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.